About Gero

GERO.AI utilizes Whole-Exome Sequencing data for in-human AI Drug Discovery, while GeroSense is the arm of Gero creating Digital Biomarkers. You can find more about GeroSense on the dedicated website.

About Gero

Our mission: Hacking Complex Diseases and Aging with AI for Drug Discovery and Digital Biomarkers

GERO.AI models are originating from the physics of complex dynamic systems. We have presented our unique approach in Frontiers in Genetics. We combine the potential of deep neural networks with the physical models to study dynamical processes and undersend what drives a disease.

Gero conducts high-quality research studies backed by collaboration with researchers from the leading global institutions such as the Harvard Medical School, Massachusetts Institute of Technology, University of Edinburgh, National University of Singapore, and Roswell Park Comprehensive Cancer Center to develop new therapies. The company is a regular contributor to peer-reviewed journals, including recently accepted publication in Science.

Gero is funded by AI champions, including AIMATTER founders (recently acquired by Google). In 2019, Gero was also named one of the leading companies in artificial intelligence for lifespan extension along with Google and IBM.

Gero team

Сuring the uncurable with Landau Lifshitz book and a bit of AI

Peter Fedichev

Director & Co-founder

I am doing my best to make aging history

Maxim Kholin

Director & Co-founder

Science is a pricey thing. On a mission to fund science against aging

Alex Kadet

Head of Business Development

Data Inquisitor

Konstantin Avchaciov

Data scientist - Life extension research

Ilya Sokolov

Data Scientist

Right-hand-woman to aging hackers

Olga Druzhinina

Deputy Finance Director

Understanding the Universe, while providing real-world solutions

Kirill Denisov

Junior Deep Learning Researcher

Ph.D., Head of Preclinical Development

Olga Burmistrova

Chairman of the Board

Yury Melnichek

Gero team

Сuring the uncurable with Landau Lifshitz book and a bit of AI

Peter Fedichev

Director & Co-founder

Yury Melnichek

Chairman

I am doing my best to make aging a history

Maxim Kholin

Director & Co-founder

Olga Burmistrova

Ph.D., Head of Preclinical Development

Science is a pricey thing. On a mission to fund science against aging

Alex Kadet

Head of Business Development

Data Inquisitor

Konstantin Avchaciov

Data scientist — Life extension research

Ilya Sokolov

Data Scientist

Right-hand-woman to aging hackers

Olga Druzhinina

Deputy Finance Director

Understanding the Universe, while providing real-world solutions

Kirill Denisov

Junior Deep Learning Researcher

Key collaborators

Robert J. Shmookler Reis, PhD

Longevity pioneer, Professor and Udupa Chair in Geriatrics, Reynolds Institute on Aging/Dept. of Geriatrics; Professor of Biochemistry/Molecular Biology and Pharmacology/Toxicology, Univ. of Arkansas for Medical Sciences
Brian Kennedy, PhD

Distinguished Professor of Biochemistry and Physiology, Yong Loo Lin School of Medicine, NUS, Singapore, Buck Institute for Research on Ageing, Novato, CA, USA.
Andrei Gudkov, PhD

Senior Vice President of Research Programming and Development of Roswell Park Cancer Institute.CSO of Everon Biosciences, founded in 2010 in a partnership with Roswell Park Cancer Institute with the goal of developing anti-aging medicines.
Vadim Gladyshev, PhD

Professor of Medicine, professor at Harvard Medical School & Brigham and Women's Hospital. Expert and pioneer in antioxidant/redox biology
Yuri Aulchenko, PhD

CSO and Founder of PolyOmica
Honorary Professor of the University of Edinburgh, listed among "The World's Most Influential Scientific Minds" in the category "Molecular Biology & Genetics"by Thomson-Reuters.

Careers in GERO.AI

We are a next-gen AI for Drug Discovery company making cutting-edge science and continuously looking for great people to join a fast-growing team of like-minded pioneers to solve some of the most critical problems humanity faces.

We are looking for:

Send CV